Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large decline in short interest in April. As of April 30th, there was short interest totaling 36,638 shares, a decline of 38.3% from the April 15th total of 59,393 shares. Approximately 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 97,175 shares, the days-to-cover ratio is presently 0.4 days.

Cyclacel Pharmaceuticals Trading Down 5.1%

NASDAQ:BGMS traded down $0.05 during trading hours on Friday, hitting $1.00. 14,800 shares of the company’s stock traded hands, compared to its average volume of 68,712. Cyclacel Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $34.65. The company has a fifty day moving average of $0.99. The company has a market cap of $5.50 million, a price-to-earnings ratio of -0.22 and a beta of -0.49.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.